Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modular Phase 2a Study of DNA-damage Response Agents in Advanced Cancer with Molecular Alterations
2020-002529-27Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib in cancer, sponsored by AstraZeneca. Primary endpoint: Objective response rate (Module 1). Started Nov 2020; status: active.
02
Drugs
ceralasertib
03
Conditions
cancer
Beyond the preview
Go deeper on 2020-002529-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002529-27.